{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:01:49Z","timestamp":1773270109839,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The current study investigated the extent of knowledge and care regimen regarding the possible risks of cardiac dysfunction from Trastuzumab (Herceptin) treatment in women with either a diagnosis of primary or metastatic breast cancer who had undergone or were receiving Trastuzumab at the time of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In a qualitative interview, participants were asked questions regarding awareness of cardiac risks of Trastuzumab therapy and knowledge of cardiac damage symptoms, as well as questions concerning the regimen of heart function monitoring during and beyond their course of treatment. Thematic analysis was used to analyse the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The emerging themes from the thematic analysis revealed inconsistencies in (a) knowledge and awareness of cardiac damage risk prior to taking Trastuzumab, (b) monitoring of cardiac function and risks of cardiac dysfunction during and beyond treatment, and (c) awareness of signs of possible cardiac damage of Trastuzumab during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that patients feel unsupported and ill-informed about the possible risks of cardiac damage from Trastuzumab. This has implications for the self-management of symptoms and mitigation of risks for cardiac damage and suggests the need for improvement in patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10357-y","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:05:49Z","timestamp":1770275149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u2018Patients are left not knowing\u2019: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer\u2014a qualitative study of patient experience"],"prefix":"10.1007","volume":"34","author":[{"given":"Karina","family":"Dolgilevica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-4435","authenticated-orcid":false,"given":"Nazanin","family":"Derakshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"10357_CR1","unstructured":"Risks and causes of breast cancer \u00a6 Cancer Research UK.\u00a0 https:\/\/www.cancerresearchuk.org\/about-cancer\/breast-cancer\/risks-causes"},{"key":"10357_CR2","unstructured":"Breast cancer facts | Breast Cancer Now. https:\/\/breastcancernow.org\/about-us\/why-we-do-it\/breast-cancer-facts-and-statistics"},{"issue":"4905","key":"10357_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"16","key":"10357_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684","journal-title":"N Engl J Med"},{"issue":"10087","key":"10357_CR5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415\u20132429","journal-title":"Lancet"},{"issue":"16","key":"10357_CR6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672","journal-title":"N Engl J Med"},{"issue":"19","key":"10357_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","volume":"32","author":"SH Giordano","year":"2014","unstructured":"Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(19):2078\u20132099","journal-title":"J Clin Oncol"},{"issue":"14","key":"10357_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283","journal-title":"N Engl J Med"},{"key":"10357_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"N Denduluri","year":"2016","unstructured":"Denduluri N, Somerfield MR, Eisen A et al (2016) Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol 34:2416\u20132427","journal-title":"J Clin Oncol"},{"issue":"12","key":"10357_CR10","doi-asserted-by":"publisher","first-page":"e0275321","DOI":"10.1371\/journal.pone.0275321","volume":"17","author":"C Jackson","year":"2022","unstructured":"Jackson C, Finikarides L, Freeman ALJ (2022) The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis. PLoS ONE 17(12):e0275321","journal-title":"PLoS ONE"},{"issue":"5","key":"10357_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","volume":"21","author":"HD Long","year":"2016","unstructured":"Long HD, Lin YE, Zhang JJ et al (2016) Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis. Oncologist 21(5):547\u2013554","journal-title":"Oncologist"},{"key":"10357_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","volume":"177","author":"G Jerusalem","year":"2019","unstructured":"Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177:237\u2013250","journal-title":"Breast Cancer Res Treat"},{"key":"10357_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N et al (2021) Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 188:21\u201336","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10357_CR14","first-page":"CD006242","volume":"12","author":"S Balduzzi","year":"2014","unstructured":"Balduzzi S, Mantarro S, Guarneri V et al (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 12(6):CD006242","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10357_CR15","first-page":"1717","volume":"33","author":"A Carmichael","year":"2013","unstructured":"Carmichael A, Rea D, Sintler M (2013) Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 33(4):1717\u20131720","journal-title":"Anticancer Res"},{"key":"10357_CR16","doi-asserted-by":"crossref","unstructured":"Tarantini L, Cioffi G, Gori S, Italian Cardio-Oncologic Network et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18(2):113\u2013119","DOI":"10.1016\/j.cardfail.2011.10.015"},{"key":"10357_CR17","unstructured":"Product Monograph - Roche. https:\/\/assets.roche.com\/f\/173850\/x\/d6bc7ff324\/herceptin_pm_e.pdf"},{"issue":"2","key":"10357_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77\u2013101","journal-title":"Qual Res Psychol"},{"key":"10357_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-69909-7_3470-2","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"V Braun","year":"2022","unstructured":"Braun V, Clarke V (2022) Thematic Analysis. In: Maggino F (ed) Encyclopedia of Quality of Life and Well-Being Research. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-319-69909-7_3470-2"},{"issue":"9","key":"10357_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","volume":"16","author":"S Martel","year":"2017","unstructured":"Martel S, Maurer C, Lambertini M et al (2017) Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf 16(9):1021\u20131038","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10357_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1037\/a0021466","volume":"137","author":"S Kim","year":"2011","unstructured":"Kim S, Thibodeau R, Jorgensen RS (2011) Shame, guilt, and depressive symptoms: a meta-analytic review. Psychol Bull 137(1):68\u201396","journal-title":"Psychol Bull"},{"issue":"12","key":"10357_CR22","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1038\/s41380-020-00865-6","volume":"25","author":"X Wang","year":"2020","unstructured":"Wang X, Wang N, Zhong L et al (2020) Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Molecular Psychiatry 25(12):3186\u20133197","journal-title":"Molecular Psychiatry"},{"issue":"12","key":"10357_CR23","doi-asserted-by":"publisher","first-page":"e0260481","DOI":"10.1371\/journal.pone.0260481","volume":"16","author":"OJ Adeyemi","year":"2021","unstructured":"Adeyemi OJ, Gill TL, Paul R, Huber LB (2021) Evaluating the association of self-reported psychological distress and self-rated health on survival times among women with breast cancer in the U.S. PLoS ONE 16(12):e0260481","journal-title":"PLoS ONE"},{"issue":"9","key":"10357_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/heartjnl-2023-323437","volume":"110","author":"C Glen","year":"2024","unstructured":"Glen C, Morrow A, Roditi G et al (2024) Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart 110(9):650\u2013656","journal-title":"Heart"},{"issue":"10","key":"10357_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","volume":"34","author":"CT Dang","year":"2016","unstructured":"Dang CT, Yu AF, Jones LW et al (2016) Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter. J Clin Oncol 34(10):1030\u20131033","journal-title":"J Clin Oncol"},{"issue":"5","key":"10357_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","volume":"21","author":"SC Seferina","year":"2016","unstructured":"Seferina SC, de Boer M, Derksen MW et al (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 21(5):555\u2013562","journal-title":"Oncologist"},{"issue":"31","key":"10357_CR27","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1093\/eurheartj\/ehad268","volume":"44","author":"JM Leerink","year":"2023","unstructured":"Leerink JM, Ehrhardt MJ, van Dalen EC (2023) A call for harmonized surveillance recommendations in cardio-oncology. Eur Heart J 44(31):3017\u20133018","journal-title":"Eur Heart J"},{"issue":"9","key":"10357_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/1060028016654160","volume":"50","author":"CC Davis","year":"2016","unstructured":"Davis CC, Zelnak A, Eley JW et al (2016) Clinical utility of routine cardiac monitoring in breast cancer patients receiving trastuzumab. Ann Pharmacother 50(9):712\u2013717","journal-title":"Ann Pharmacother"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10357-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:44:15Z","timestamp":1773215055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10357-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10357"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10357-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the School of Psychology and Clinical Language Sciences at the University of Reading (Reference number: 2023-021-ND) and carried out in accordance with the Helsinki Declaration.Informed consentAll participants gave informed consent prior to taking part in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}